Advertisement

Prophylactic Treatment of the Pelvic Lymphatics: Contra

  • Pascal Pommier
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

According to the opinion of the author, to date—applying evidence-based medicine—physicians should not perform prophylactic pelvic lymph node irradiation in routine practice for locally advanced prostate cancer because of the lack of any demonstrated benefit. In addition, this treatment has a higher risk of acute and late toxicities. Standard prognostic factors and nomograms, failed to identify a subgroup of patients who may benefit from pelvic lymph nodes irradiation. Several biases including technical radiotherapy features (target volume, dose) are discussed. Radiation oncologists should be encouraged to participate in the ongoing RTOG 094 international randomized study.

Keywords

Lymph Node Involvement Advanced Prostate Cancer Pelvic Radiotherapy Biologic Effective Dose Partin Table 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15(6):1307–1316PubMedCrossRefGoogle Scholar
  2. Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40(4):769–782PubMedCrossRefGoogle Scholar
  3. Briganti A, Chun FK, Karakiewicz P et al (2008) Is node-positive prostate cancer always a systemic disease? Eur Urol 54(2):243–246Google Scholar
  4. Briganti A, Karnes J, Da Pozzo L et al (2008b) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 784 consecutive N+ patients. Eur Urol 7:303CrossRefGoogle Scholar
  5. Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. a new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270PubMedCrossRefGoogle Scholar
  6. Briganti A, Larcher A, Abdollah F et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487PubMedCrossRefGoogle Scholar
  7. D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974PubMedCrossRefGoogle Scholar
  8. Ganswindt U, Paulsen F, Corvin S et al (2007) Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 67(2):347–355PubMedCrossRefGoogle Scholar
  9. Guerrero Urbano T, Khoo V, Staffurth J et al (2010) Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin Oncol (R Coll Radiol) 22(3):236–244CrossRefGoogle Scholar
  10. Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52:29–37PubMedCrossRefGoogle Scholar
  11. Hwang AB, Chen J, Nguyen TB et al (2012) Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm. Med Phys 39(2):1119–1124PubMedCrossRefGoogle Scholar
  12. Jacob R, Hanlon AL, Horwitz EM et al (2005) Role of prostate dose escalation in patients with greater than 15 % risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61:695–701PubMedCrossRefGoogle Scholar
  13. Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897PubMedCrossRefGoogle Scholar
  14. Jilg CA, Rischke HC, Reske SN et al (2012) Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 188(6):2190–2197PubMedCrossRefGoogle Scholar
  15. Lawton CA, DeSilvio M, Roach M et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646–655PubMedCentralPubMedCrossRefGoogle Scholar
  16. Lawton CA, Michalski J, El-Naqa I et al (2009) RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383–387PubMedCentralPubMedCrossRefGoogle Scholar
  17. Muren LP, Wasbø E, Helle SI et al (2008) Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences. Int J Radiat Oncol Biol Phys 71(4):1034–1041PubMedCrossRefGoogle Scholar
  18. Pan CC, Kim KY, Taylor JM (2002) Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53:1139–1145PubMedCrossRefGoogle Scholar
  19. Pilepich MV, Krall JM, Johnson RJ et al (1986) Extended field (periaortic) irradiation in carcinoma of the prostate–analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 12(3):345–351PubMedCrossRefGoogle Scholar
  20. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105PubMedCrossRefGoogle Scholar
  21. Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366–5373PubMedCrossRefGoogle Scholar
  22. Roach M, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37PubMedCrossRefGoogle Scholar
  23. Roach M III, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911PubMedCrossRefGoogle Scholar
  24. Roach M 3rd, DeSilvio M, Valicenti R et al (2006) Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation therapy oncology group 9413 trial. Int J Radiat Oncol Biol Phys 66(3):647–653PubMedCrossRefGoogle Scholar
  25. Shih H, Harisinghani M, Zietman A et al (2005) Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 63:1262–1269PubMedCrossRefGoogle Scholar
  26. Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph node-positive prostate cancer. Cancer 106(12):2531–2539PubMedCrossRefGoogle Scholar
  27. Taylor A, Rockall A, Reznek R et al (2005) Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63:1604–1612PubMedCrossRefGoogle Scholar
  28. Vargas CE, Galalae R, Demanes J et al (2005) Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 63:1474–1482PubMedCrossRefGoogle Scholar
  29. Vargas C, Martínez A, Galalae R et al (2006) High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis 9(3):245–253PubMedCrossRefGoogle Scholar
  30. Walz J, Bladou F, Rousseau B et al (2012) Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. Urology 79(3):546–551PubMedCrossRefGoogle Scholar
  31. Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M 3rd (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66(3):654–662PubMedCrossRefGoogle Scholar
  32. Weckermann D, Goppelt M, Dorn R et al (2006) Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or = 10 ng/mL and biopsy Gleason score of < or = 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 97(6):1173–1178PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Radiotherapy DepartmentCentre Léon BérardLyon CEDEX 08France

Personalised recommendations